Newsroom - Page 10

Poster presentations at the American Diabetes Association Scientific Sessions compared canagliflozin, an SGLT2 inhibitor, to sitagliptin, a popular DPP-4 inhibitor, using claims data.
A poster at an ADA session on barriers and facilitators to novel care found that top concerns of patients with diabetes often have nothing to do with the disease. Other studies looked at which comorbidities contribute the most to readmissions or length of stay, and how an intervention that focused on transitions of care reduced A1C in patients with uncontrolled diabetes.
Robert M. Anderson, EdD, of the University of Michigan, has spent his career spreading a message that patients respond best when education programs address what they want, not what an expert thinks they need.
Treatment for Duchenne muscular dystrophy remains in flux with the FDA delaying a decision on Sarepta's treatment and Biomarin discontinuing development on its own drug.
Two studies presented at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure held in Florence, Italy, hold good news for patients with heart failure who get flu shots.
Speakers at the 76th Scientific Sessions of the American Diabetes Association discussed current donor transplant successes and engineering challenges of efforts to generate islet cells in the laboratory.
This week in managed care, the top stories included discussions on biomarkers and financial toxicity at the annual meeting of the American Society of Clinical Oncology, and a preview of the 76th Scientific Sessions of the American Diabetes Association.
In an ADA session called "Follow the Money," panelists led by Joslin Diabetes Center's Robert A. Gabbay, MD, PhD, FACP, discussed the diabetes cost burden, insulin costs, and payment models.
Diabetes Compendium
Oncology Compendium
Reimbursement Compendium
Know Your News
HF Compendium